| Abstrakt: |
Keywords: Bethesda; State:Maryland; United States; North and Central America; Antibodies; Antineoplastics; BCL-2 Inhibitors; Bispecific Antibodies; Blood Proteins; Drugs and Therapies; Immunoglobulins; Immunology; Immunoproteins; Pharmaceuticals; Proteins; Therapy; Venetoclax Therapy EN Bethesda State:Maryland United States North and Central America Antibodies Antineoplastics BCL-2 Inhibitors Bispecific Antibodies Blood Proteins Drugs and Therapies Immunoglobulins Immunology Immunoproteins Pharmaceuticals Proteins Therapy Venetoclax Therapy 1147 1147 1 09/19/23 20230919 NES 230919 2023 SEP 19 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- A new study on Drugs and Therapies - Antineoplastics is now available. To characterize epcoritamab-mediated cytotoxicity against primary CLL cells, peripheral blood mononuclear cells from treatment-naive and BTKi-treated patients, including patients progressing on therapy, were cultured with epcoritamab alone or in combination with venetoclax. Bethesda, State:Maryland, United States, North and Central America, Antibodies, Antineoplastics, BCL-2 Inhibitors, Blood Proteins, Drugs and Therapies, Immunoglobulins, Immunology, Immunoproteins, Pharmaceuticals, Proteins, Therapy, Venetoclax Therapy, Bispecific Antibodies. [Extracted from the article] |
